Where does O6 -methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma?

Abstract

Methylation of the promoter region of the O6‐methylguanine DNA methyltransferase (MGMT) gene has emerged as the first—and so far the only—predictive biomarker for glioblastoma. Challenges in establishing a reliable assay to interrogate MGMT promoter methylation status and the lack of therapeutic alternatives to alkylating agent chemotherapy remain hurdles in the global implementation of MGMT testing as part of the standard of care.